(BBIO) BridgeBio Pharma - Ratings and Ratios
ATTR-CM, Achondroplasia, Hypochondroplasia, ADH1, LGMD2I
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 50.8% |
| Value at Risk 5%th | 76.1% |
| Relative Tail Risk | -8.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.85 |
| Alpha | 105.76 |
| CAGR/Max DD | 2.23 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.407 |
| Beta | 1.011 |
| Beta Downside | 0.801 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.08% |
| Mean DD | 20.38% |
| Median DD | 19.76% |
Description: BBIO BridgeBio Pharma January 07, 2026
BridgeBio Pharma (NASDAQ: BBIO) is a commercial-stage biopharma founded in 2015 and based in Palo Alto, California. It focuses on developing small-molecule and gene-therapy treatments for rare genetic disorders and oncology, leveraging a platform that pairs disease-genetics insight with in-house drug discovery.
The current pipeline includes: (1) Attruby, a next-generation oral TTR stabilizer in late-stage development for transthyretin-mediated cardiomyopathy (ATTR-CM); (2) low-dose infigratinib, an FGFR1-3 selective inhibitor advancing in a Phase 3 double-blind trial for achondroplasia and in a Phase 2/3 study for hypochondroplasia; (3) Encaleret, a CaSR antagonist in Phase 3 for autosomal dominant hypocalcemia type 1; and (4) BBP-418, a glycosylation-substrate pro-drug in Phase 3 for limb-girdle muscular dystrophy type 2I/R9. The company also maintains collaborations with Alexion, Stanford, Leidos, and Novartis to broaden its Mendelian and oncology portfolio.
As of the latest 10-Q (Q2 2024), BridgeBio reported a market capitalization of roughly $2.4 billion, cash and equivalents of $450 million, and a cash burn rate of about $120 million per quarter, giving it just over a year of runway without additional financing. The biotech sector is benefiting from a 10-12 % CAGR in rare-disease drug approvals and increasing payer willingness to reimburse high-value therapies, which supports higher valuation multiples for companies with late-stage assets.
For a deeper, data-driven look at BBIO’s valuation and risk profile, you might explore the analyst tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -797.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.60 > 0.02 and ΔFCF/TA 9.00 > 1.0 |
| NWC/Revenue: 176.0% < 20% (prev 140.2%; Δ 35.81% < -1%) |
| CFO/TA -0.59 > 3% & CFO -584.8m > Net Income -797.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (190.5m) vs 12m ago 1.06% < -2% |
| Gross Margin: 95.78% > 18% (prev 0.99%; Δ 9479 % > 0.5%) |
| Asset Turnover: 42.54% > 50% (prev 32.75%; Δ 9.79% > 0%) |
| Interest Coverage Ratio: -5.63 > 6 (EBITDA TTM -677.3m / Interest Expense TTM 121.3m) |
Altman Z'' -14.58
| A: 0.62 (Total Current Assets 839.4m - Total Current Liabilities 216.6m) / Total Assets 998.2m |
| B: -3.63 (Retained Earnings -3.63b / Total Assets 998.2m) |
| C: -0.82 (EBIT TTM -682.6m / Avg Total Assets 831.6m) |
| D: -1.24 (Book Value of Equity -3.63b / Total Liabilities 2.92b) |
| Altman-Z'' Score: -14.58= D |
Beneish M 1.00
| DSRI: 150.0 (Receivables 116.5m/478.0k, Revenue 353.8m/217.8m) |
| GMI: 1.03 (GM 95.78% / 98.90%) |
| AQI: 0.48 (AQ_t 0.15 / AQ_t-1 0.31) |
| SGI: 1.62 (Revenue 353.8m / 217.8m) |
| TATA: -0.21 (NI -797.1m - CFO -584.8m) / TA 998.2m) |
| Beneish M-Score: 119.6 = D |
ValueRay F-Score (Strict, 0-100) 48.46
| 1. Piotroski: 2.0pt |
| 2. FCF Yield: -3.74% |
| 3. FCF Margin: data missing |
| 4. Debt/Equity: -0.96 |
| 5. Debt/Ebitda: data missing |
| 7. RoE: 46.63% |
| 8. Revenue Trend: 46.69% |
| 9. EPS Trend: -3.37% |
What is the price of BBIO shares?
Over the past week, the price has changed by +4.79%, over one month by +3.66%, over three months by +50.09% and over the past year by +122.96%.
Is BBIO a buy, sell or hold?
- Strong Buy: 10
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 89 | 11.3% |
| Analysts Target Price | 89 | 11.3% |
| ValueRay Target Price | 92.1 | 15.3% |
BBIO Fundamental Data Overview January 17, 2026
P/B = 123.6828
Revenue TTM = 353.8m USD
EBIT TTM = -682.6m USD
EBITDA TTM = -677.3m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 5.29m USD (from shortTermDebt, last quarter)
Debt = 1.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.22b USD (from netDebt column, last quarter)
Enterprise Value = 15.91b USD (14.70b + Debt 1.86b - CCE 645.9m)
Interest Coverage Ratio = -5.63 (Ebit TTM -682.6m / Interest Expense TTM 121.3m)
EV/FCF = -26.73x (Enterprise Value 15.91b / FCF TTM -595.2m)
FCF Yield = -3.74% (FCF TTM -595.2m / Enterprise Value 15.91b)
FCF Margin = -168.2% (FCF TTM -595.2m / Revenue TTM 353.8m)
Net Margin = -225.3% (Net Income TTM -797.1m / Revenue TTM 353.8m)
Gross Margin = 95.78% ((Revenue TTM 353.8m - Cost of Revenue TTM 14.9m) / Revenue TTM)
Gross Margin QoQ = 94.56% (prev 96.70%)
Tobins Q-Ratio = 15.94 (Enterprise Value 15.91b / Total Assets 998.2m)
Interest Expense / Debt = 0.63% (Interest Expense 11.7m / Debt 1.86b)
Taxrate = 21.0% (US default 21%)
NOPAT = -539.3m (EBIT -682.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.88 (Total Current Assets 839.4m / Total Current Liabilities 216.6m)
Debt / Equity = -0.96 (negative equity) (Debt 1.86b / totalStockholderEquity, last quarter -1.93b)
Debt / EBITDA = -1.80 (negative EBITDA) (Net Debt 1.22b / EBITDA -677.3m)
Debt / FCF = -2.04 (negative FCF - burning cash) (Net Debt 1.22b / FCF TTM -595.2m)
Total Stockholder Equity = -1.71b (last 4 quarters mean from totalStockholderEquity)
RoA = -95.85% (Net Income -797.1m / Total Assets 998.2m)
RoE = 46.63% (negative equity) (Net Income TTM -797.1m / Total Stockholder Equity -1.71b)
RoCE = -481.7% (out of range, set to none) (EBIT -682.6m / Capital Employed (Equity -1.71b + L.T.Debt 1.85b))
RoIC = -498.4% (out of range, set to none) (NOPAT -539.3m / Invested Capital 108.2m)
WACC = 8.61% (E(14.70b)/V(16.56b) * Re(9.64%) + D(1.86b)/V(16.56b) * Rd(0.63%) * (1-Tc(0.21)))
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.50%
Fair Price DCF = unknown (Cash Flow -595.2m)
EPS Correlation: -3.37 | EPS CAGR: 14.10% | SUE: 0.39 | # QB: 0
Revenue Correlation: 46.69 | Revenue CAGR: 81.59% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.60 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.77 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+44.4% | Growth Revenue=+79.5%
Additional Sources for BBIO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle